RecruitingPhase 3NCT06952504
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Sponsor: Merck Sharp & Dohme LLC
Centerville, OH · Cincinnati, OH · Columbus, OH · +50 more sites